A phase 2 randomised study of veliparib plus FOLFIRI +/- bevacizumab versus placebo plus FOLFIRI +/- bevacizumab in metastatic colorectal cancer (vol 120, pg 183, 2019)

dc.contributor.author	Berlin, Jordan D.
dc.date.accessioned	2020-07-21T21:15:54Z
dc.date.available	2020-07-21T21:15:54Z
dc.date.issued	2019-08-27
dc.description	Correction to: British Journal of Cancer (2019) 120, 183–189; 10.1038/s41416-018-0343-z; published online 11 December 2018 The original version of this article contained an error in Fig. 1a. The number of patients at risk listed in the Veliparib arm of Fig. 1a should have read “65” instead of “35”. The correct figure is below.	en_US
dc.identifier.citation	Gorbunova V, Beck JT, Hofheinz RD, et al. Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. Br J Cancer. 2019;121(5):429-430. doi:10.1038/s41416-019-0528-0	en_US
dc.identifier.issn	0007-0920
dc.identifier.uri	http://hdl.handle.net/1803/10226
dc.language.iso	en_US	en_US
dc.publisher	British Journal of Cancer	en_US
dc.title	A phase 2 randomised study of veliparib plus FOLFIRI +/- bevacizumab versus placebo plus FOLFIRI +/- bevacizumab in metastatic colorectal cancer (vol 120, pg 183, 2019)	en_US
dc.type	Article	en_US

Files

Now showing 1 - 1 of 1

Name:: Correction_A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.pdf
Size:: 448.71 KB
Format:: Adobe Portable Document Format
Description:

Now showing 1 - 1 of 1